Immune-Onc Therapeutics and Roche Collaborate to Develop IO-108 for Treating Advanced Hepatocellular Carcinoma
Shots:
- Immune-Onc has entered into a clinical trial collaboration with Roche to investigate the former’s IO-108, combined with Roche’s Tecentriq and Avastin to treat locally advanced/metastatic unresectable hepatocellular carcinoma (HCC)
- Under the partnership, Immune-Onc will provide IO-108 while retaining its ownership worldwide and Roche will be responsible for the trial’s funding along with its operations
- The P-Ib/II study, a part of Roche’s Morpheus-Liver program, aims to determine the efficacy of IO-108 + Tecentriq & Avastin vs Tecentriq + Avastin (SoC) for treating patients (n=40 in the triplet arm) with locally advanced/metastatic unresectable HCC without previous systemic treatment
Ref: Immune-Onc Therapeutics | Image: Immune-Onc Therapeutics
Related News:- Roche Reports the US FDA’s Approval of Xolair for Treating Food Allergies
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
